Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

(Loss) Income per Common Share

(Loss) Income per Common Share

9 Months Ended

Aug. 31, 2016

Earnings Per Share [Abstract]

(Loss) Income per Common Share

Note 8 – (Loss) Income per Common Share

The following table sets forth the calculation of basic and diluted net (loss) income per common share:


	Three Months Ended					Nine Months Ended
	August 31, 2016			August 31, 2015		August 31, 2016			August 31, 2015
Numerator:
Net (Loss) Income	($	2,644,361	)	$	7,829,572		(2,130,165	)	$	8,325,774

Denominator:
Weighted-average shares outstanding-basic		7,583,771			9,462,102		8,546,110			9,697,679
Dilutive common shares issuable upon exercise of stock options		—			288,095		—			247,939

Weighted-average shares-diluted		7,583,771			9,750,197		8,546,110			9,945,618

Net (loss) income per common share:
Basic	($	0.35	)	$	0.83	($	0.25	)	$	0.86

Diluted	($	0.35	)	$	0.80	($	0.25	)	$	0.84

For the three and nine months ended August 31, 2016, the Company excluded the effect of all outstanding stock options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive.

For the three and nine months ended August 31, 2015, the Company excluded the effect of 225,000 and 287,500, respectively, outstanding options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive.